Journal of Neuro-Oncology

, Volume 5, Issue 4, pp 339–350

The effects of diphenylhydantoin on murine astrocytoma radiosensitivity

  • Carl D. Lordo
  • Eric C. Stroude
  • Rolando F. Del Maestro
Article

Summary

Diphenylhydantoin is a well known anticonvulsant used primarily in the treatment of epilepsy. The prophylactic use of diphenylhydantoin has been suggested for certain cerebral metastases, and it is routinely administered to prevent seizures induced by intracranial neoplasms and/or surgery. Patients with malignant gliomas treated with diphenylhydantoin frequently receive radiation therapy. The effects of a clinical concentration of diphenylhydantoin in combination with gamma radiation was investigated using the C6 astrocytoma cell line in both monolayer and three dimensional multicellular spheroid cultures.

Diphenylhydantoin at 7.2 × 10-5 M (20 µg/ml) significantly increased the doubling time (23%) of the C6 astrocytoma cells in monolayer, but did not affect their survival as measured by plating efficiency. No changes were seen in spheroid growth or plating efficiency of the cells dissociated from spheroids at this concentration.

Diphenylhydantoin at the clinical concentration tested was not associated with an alteration in radiation sensitivity of C6 astrocytoma cells in monolayer or three dimensional multicellular spheroid cultures.

Key words

diphenylhydantoin glioblastoma gamma radiation murine astrocytoma multicellular spheroids 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Garfield J: Surgery of cerebral gliomas. In: Thomas DGT, Graham DI (eds) Brain Tumours: Scientific Basis, Clinical Investigation and Current Therapy. Butterworth and Co. Ltd., London, England, 1980, pp 301–321Google Scholar
  2. 2.
    Sheline GE: Radiation therapy of primary tumours. Sem Oncol 2:29–42, 1975Google Scholar
  3. 3.
    Walker MD, Gehan EA: Clinical studies in malignant gliomas and the treatment with nitrosourea. Cancer Treat Rep 60:713–716, 1976Google Scholar
  4. 4.
    Walker MD, Alexander Jr E, Hunt WE, MacCarty CS, Mahaley Jr MS, Mealey Jr J, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial. J Neurosurg 49:333–343, 1978Google Scholar
  5. 5.
    Byrne TN, Cascino TL, Posner JB: Brain metastasis from melanoma. J Neuro-Oncology 1:313–317, 1983Google Scholar
  6. 6.
    Woodbury DM: Phenytoin: Mechanisms of action. In: Woodbury DM, Penry JK, Pippenger CE (eds) Antiepileptic Drugs. Raven Press, New York, 1982, pp 269–281Google Scholar
  7. 7.
    Goldberg MA: Phenytoin, phospholipids and Calcium. Neurology 27:827–833, 1977Google Scholar
  8. 8.
    Pincus JH, Lee SH: Diphenylhydantoin and Calcium. Arch Neurol 29:239–244, 1973Google Scholar
  9. 9.
    Sohn RS, Ferrendelli JA: Inhibition of Ca++ transport into rat brain synaptosomes by diphenylhydantoin. J Pharmacol Exp Ther 185:272–275, 1973Google Scholar
  10. 10.
    Siesjo BK: Cell damage in the brain: A speculative synthesis. J Cerebral Blood Flow and Metabolism 1:155–185, 1981Google Scholar
  11. 11.
    Cullen JP, Aldrete JA, Jankovsky L, Romo-Salas F: Protective action of phenytoin in cerebral ischemia. Anesth Analg 58:165–169, 1979Google Scholar
  12. 12.
    Aldrete JA, Romo-Salas F, Jankovsky L, Franatovic Y: Effect of pretreatment with thiopental and phenytoin on postischemic brain damage in rabbits. Crit Care Med 7:466–470, 1979Google Scholar
  13. 13.
    Baum H, Booth RFG: Transmembrane calcium fluxes and cell death. In: Benga G, Baum H, Kummerow FA (eds) Membrane Processes. Molecular biology and medical applications. New York, Springer-Verlag, 1984, pp 167–176Google Scholar
  14. 14.
    Hall EJ: Radiobiology for the radiologist. Harper and Row Publishers Inc. New York, 1978Google Scholar
  15. 15.
    Sutherland RM, McCredie JA, Inch WR: Growth of multicellular spheroids in tissue culture as a model of nodular carcinoma. J Nat Cancer Inst 46:113–120, 1971Google Scholar
  16. 16.
    Chary S, Stroude E, Tustanoff ER, Inch WR: Effect of cimetidine on growth and radiosensitivity of V79 multicell spheroids. J Clin Hema and Oncology 14(3):83–90, 1984Google Scholar
  17. 17.
    Grissette DE, Stewart SE, Coker ST, Davidson PP, Williams BB: Biologic interaction of gamma radiation with phenylbutazone, phenytoin or hydralazine. Res Comm Chem Path and Pharm 29(3):589–597, 1980Google Scholar
  18. 18.
    Farrell CL, Stewart PA, Del Maestro RF: A new glioma model in rat: The C6 astrocytoma spheroid implantation technique, permeability and vascular characterization. J Neuro-Oncology 4:403–415, 1987Google Scholar
  19. 19.
    Lu-Steffes M, Jolley M, Pittluck G, Panas H, et al.: Fluorescence polarization immunoassays of phenytoin and phenobarbital. Clin Chem 27:1093, 1981Google Scholar
  20. 20.
    Benda P, Lightbody J, Sato G, Levine L, Sweet W: Differentiated rat glial cell strain in tissue culture. Sci 161:370–371, 1968Google Scholar
  21. 21.
    Auer RN, Del Maestro RF, Anderson R: A simple and reproducible experimental in vivo glioma model. Can J Neurol Sci 8(4):325–331, 1981Google Scholar
  22. 22.
    Franko J: Oxygen diffusion in the multicellular spheroid in vitro tumor model: effects on cell survival and radiation response. Thesis, Department of Biophysics, University of Western Ontario, 1976Google Scholar
  23. 23.
    Stewart PA, Hayakawa K, Hayakawa E, Farrell CL, Del Maestro RF: A quantitative study of blood-brain barrier permeability ultrastructure in a new rat glioma model. Acta Neuropathologica 67:96–102, 1985Google Scholar
  24. 24.
    Reichman HR, Farrell CL, Del Maestro RF: Effects of steroids and nonsteroid anti-inflammatory agents on vascular permeability in a rat glioma model. J Neurosurg 65:233–237, 1986Google Scholar
  25. 25.
    Kornblith PL, Hartnett BA, Anderson LP, Quindlen EA, Smith BH: Growth inhibitory effect of diphenylhydantoin and murine astrocytomas. Neurosurgery 5(2):259–263, 1979Google Scholar
  26. 26.
    Fowler JF: Hypoxic cell radiosensitizers, present status and future promise. In: Meyn RE, Withers RH (eds) Radiation Biology in Cancer Research. Raven Press, New York, 1980, pp 533–546Google Scholar
  27. 27.
    Adams GE: Hypoxic cell sensitizers for radiotherapy. In: Becker FF (ed) Cancer: A Comprehensive Treatise. Plenum Press, New York, 1977, pp 181–223Google Scholar
  28. 28.
    Kerr JFR, Bishop CF, Searle F: Apoptosis. In: Anthony PP, Mac Sween RNM (eds) Recent advances in histopathology. Churchill Livingstone, New York, 1984, pp 1–16Google Scholar
  29. 29.
    Kerr JFR, Searle J: Apoptosis: Its nature and kinetic role. In: Meyn RE, Withers RH (eds) Radiation Biology in Cancer Research. Raven Press, New York, 1980, pp 367–384Google Scholar
  30. 30.
    Wyllie AH, Kerr JFR, Currie AR: Cell death: the significance of apoptosis. International Review of Cytology 68:251–306, 1980Google Scholar
  31. 31.
    Kaltman RF, Rockwell S: Effects of radiation on animal tumor models. In: Becker FF (ed) Cancer: A Comprehensive Treatise. Plenum Press, New York, 1977, pp 225–279Google Scholar
  32. 32.
    Durand RE, Sutherland RM: Dependence of radiation response of an in vitro tumor model on cell cycle effects. Cancer Research 33:213–219, 1973Google Scholar
  33. 33.
    Levy RH: Antiepileptic Drugs. Phenytoin: Biopharmacology. In: Glaser GH, Penry JK, Woodbury DM (eds) Antiepileptic Drugs: Mechanisms of Action. Raven Press, New York, 1980, pp 315–321Google Scholar

Copyright information

© Martinus Nijhoff Publishers 1987

Authors and Affiliations

  • Carl D. Lordo
    • 1
  • Eric C. Stroude
    • 1
  • Rolando F. Del Maestro
    • 1
  1. 1.Brain Research Laboratory, Department of Clinical Neurological Sciences and Biophysics, Victoria HospitalUniversity of Western OntarioLondonCanada
  2. 2.Brain Research Laboratory, Department of Clinical Neurological SciencesVictorial HospitalLondonCanada

Personalised recommendations